MDS
Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. MDS are a collection of myeloid malignancies characterized by one or more peripheral blood cytopenias. Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
The EC approval of luspatercept was based on results from the phase II BEYOND study.
Treatment of LR-MDS remains an unmet need and goals of therapy should extend beyond transfusion independence.
MDS/AML are among independent predictors of COVID-19 treatment failure.
Oxidized mitochondrial DNA can “prime” MDS HSPCs for inflammasome activation.
Low-risk MDS can have high-risk features, but current MDS prognostic scoring systems may not capture key risk variables.
While the fifth edition “softened” the boundary between MDS and AML, it retains the 20% blast cutoff to define AML.
Exposure to thalidomide analogs is associated with TP53 mutations in patients with therapy-related myeloid neoplasms.
Luspatercept reduced RBC transfusion units and visits in patients with lower-risk MDS with ring sideroblasts.
A panel recently made a consensus proposal to revise the IWG response criteria for higher-risk MDS.
The U.S. FDA granted Fast Track Designation to tamibarotene, an oral selective RARα agonist, for higher-risk MDS.
Sanam Loghavi, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about why 2022 was a major year for MDS.
A participant’s death led to a voluntary pause of a phase I/II trial evaluating MGTA-117 in relapsed/refractory AML and ...
Long-term safety data for luspatercept showed no new safety signals in lower-risk MDS.
Venetoclax plus azacitidine provided “clinically meaningful benefits” in R/R/ MDS post-HMA failure.
Researchers have developed and externally validated a clinical-molecular prognostic model for risk stratification in MDS.
Patients with MDS who received active therapy soon after their diagnosis had better outcomes than those who did not.
DocMatter members weigh in on the use of venetoclax in patients with higher-risk myelodysplastic syndromes.
Survival rates for MDS/MPN overlap syndromes vary significantly by clinical entity.
A phase III trial confirmed the efficacy of lenalidomide in transfusion-dependent MDS patients.
MDS patients with del5q and one additional non-del20q cytogenetic abnormality are at higher risk.
Researchers formulated an optimal dosing schedule for the oral-fixed dose combination of decitabine and cedazuridine in MDS.
Patients with MDS or AML experienced a reduction in the allele frequency of TP53 mutations in as early as cycle three.
Blast quantification modalities vary substantially and could significantly impact treatment decisions in patients with MDS.
Phillip Scheinberg, MD, talk about CHIP and the IPSS-M in MDS with Chadi Nabhan, MD, host of The HemOnc Pulse, during ASH.
Roger Lyons, MD, FACP, discusses challenges and future directions in treating patients with higher-risk MDS.
A recent study evaluated patients with rare myeloid neoplasms who had NPM1 mutations.
The IPSS-M Risk Stratification Model led to reclassification of almost half of patients with hypoplastic MDS.
The number of cells with chromosomal abnormalities was significantly associated with clinical features and outcomes in MDS.
Most patients with lower-risk MDS who had low transfusion burden before luspatercept achieved transfusion independence.
Roger Lyons, MD, FACP, discusses a real-world retrospective observational study of treatment and survival in MDS.
SX-682 was effective and well tolerated at a dose of 200 mg twice daily in patients with MDS.
A recent study evaluated the safety profile of deferiprone in patients with myelodysplastic syndromes (MDS).
A new machine-learning model based exclusively on clinical variables high prognostic accuracy for predicting MDS outcomes.
Patients with MDS or TP53-mutated acute leukemias who underwent HSCT had a one-year OS rate of 48.4%.
Venetoclax plus azacitidine maintenance after allogeneic HSCT led to a one-year OS rate of 70% in patients with AML/MDS.
More than one-third of patients with MDS and their caregivers had “concerning levels of depression and/or anxiety."
Patients aged 80 years and older and the lowest-risk patients with MDS are “more likely to die from competing causes."
A CR with partial hematologic recovery leads to "similar survival and duration on therapy” as a CR in patients with MDS.
Decitabine did not improve event-free survival over hydroxyurea in patients with advanced myeloproliferative CMML.
Eprenetapopt and azacitidine after allogeneic HSCT was well tolerated in patients with TP53-mutated AML and MDS.
Venetoclax and azacitidine in R/R MDS demonstrated a manageable safety profile with meaningful clinical benefits...
Further development of BI 836858 was discontinued after it failed to elicit a response in transfusion-dependent.
Azacitidine may be a treatment option for patients with SAID associated with MDS and CMML.
A prospective study failed to confirm the general predictive value of a biomarker-driven prediction model.
HLA-matched sibling donors are the preferred transplant choice for MDS.
A study showed "unexpected" results related to race and MDS survival...
Nearly a third (30%) of patients with higher-risk MDS have an overexpression of the RARA gene...
The classification process is mainly based on two processes, class discovery and class prediction...
Phillip Scheinberg, MD, PhD, discusses myelodysplastic syndromes at the 2022 SOHO Annual Meeting...
ASTX727 is an oral fixed-dose combination of HMA decitabine and cytidine deaminase inhibitor cedazuridine...
Blood Cancers Today interviewed Dr. Diez-Campelo after her presentation titled, “Treatment of Lower Risk MDS.”
Researchers retrospectively assessed 135 untreated patients with MDS who later developed HMA-F...
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Lionel Adès, MD, PhD, spoke with Blood Cancers Today about the session he presented at the 2022 SOHO Annual Meeting...
The outcomes of AML transformation after HMA-failure MDS remain extremely poor...
Azacitidine is the current standard of care, and magrolimab is a monoclonal antibody blocking CD47 expression...
During the 2022 SOHO Annual Meeting, Jacqueline S. Garcia, MD, discussed immunotherapies for myelodysplastic syndromes...
There was no significant difference between patients treated with azacitidine on a five-day or a five-plus-two-day schedule..
Dr. Garcia-Manero talks about what a “total approach” to MDS means to him...
The number of HSCTs performed for MDS is increasing, yet HSCT remains under-utilized for MDS...
Guillermo Garcia-Manero, MD, was honored during the society’s 10th annual meeting in Houston, Texas...
The study sought to understand the characteristics and molecular profile of h-MDS in comparison with n-MDS...
Guillermo Garcia-Manero, MD, gives his perspective.
Alexandre Bazinet, MD, and colleagues conducted the single-center, dose-expansion phase I/II trial...
It led to an overall response rate of 74% in patients with newly diagnosed IDH2-mutated myelodysplastic syndrome.
Pathogenic or likely pathogenic germline variants are found in around a fifth of patients with MDS diagnosed at or before 40.
The results of the trial were presented during the 2022 ESMO Congress by Chunkang Chang, MD, PhD.
The FDA granted Orphan Drug Designation to tamibarotene for the treatment of MDS in February 2022.
The researchers analyzed data from previously untreated adult patients with low- or intermediate-risk MDS.
The study included patients who had anemia due to lower-risk MDS with ring sideroblasts and received regular RBC transfusions
A phase II, multicenter, open-label trial found that eprenetapopt plus azacitidine was well tolerated and safe.
The trial examined selinexor's effect on treatment outcomes in patients with AML and high-risk MDS.
The global, phase III PANTHER trial investigated the comparison in higher-risk MDS, higher-risk CMML, and AML.
Guillermo Garcia-Manero, MD, discusses where the field of hematologic oncology is headed.
Dr. Garcia-Manero discusses research from the MDS/AML Moon and what he’s looking forward to as President-Elect of SOHO.
The MDS/AML Moon Shot® program supports research projects that would be difficult to obtain traditional funding for.
A retrospective study showed that response rate and survival outcome are still modest for high-risk patients.
The study analyzed 70 transplant-ineligible patients with high-risk MDS and MDS/AML with less than 30% of myeloblasts.
The new IPSS-Molecular model generates a unique risk score for individual patients.
Researchers reviewed the FDA Adverse Event Reporting System and the EudraVigilance database for adverse event reports.
Treosulfan demonstrated a significant improvement in EFS over RIC busulfan with a clinically meaningful benefit.
HMAs are currently used as a first-line treatment for patients with MDS, but their mechanism of action is not clear.
The presence of TP53-mutated MDS and AML with CK points to a single aggressive disease.
TP53-mutated AML and MDS-EB do not differ with respect to their clinical and molecular characteristics or survival outcomes.
Study finds BM CH was present in nearly two-thirds of BPDCN patients and particularly prevalent in elderly patients.
The FDA and Finnish Medicines Agency cleared the investigational new drug application for bexmarilimab.
Dr. Scheinberg talks about how his father influenced his career and how he built an advanced hematology program in Brazil.
The phase I/II study will assess the safety and tolerability of the drug.
The hold was initiated after a reported death of a trial participant.
The FDA has put a partial hold on a clinical trial of emavusertib after the death of a patient.
The hold follows reports of a discrepancy in suspected unexpected serious adverse events between treatment arms.
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Jesus D. Gonzalez-Lugo, MD, and colleagues, presented the findings at the 2021 ASH Annual Meeting.
Results from the phase II IDIOME trial suggest that ivosidenib had good tolerability and significant efficacy.
These findings were shared at the 2021 ASH Annual Meeting by investigator Elsa Bernard, PhD.
A study evaluated factors associated with intense end-of-life care among patients younger than 40 with blood cancer.
Advertisement
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
